Business
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
THOUSAND OAKS, Calif., March 16, 2026--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2025 and business updates.
About this update from Atara Biotherapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3000,"height":912,"url":"https://media.zenfs.com/en/business-wire.com/2f99529ea366ade941be128597fa5f6c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/D.CZhwoADSRGnK8jK8PSHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2f99529ea366ade941be128597fa5f6c","width":960,"height":292},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/0MM.cNtDt8xZKadMQXKGZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03MzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/2f99529ea366ade941be128597fa5f6c","width":1200,"height":365}},"lazy":false},{"type":"text","content":"Atara delivers significant operational efficiencies and extends cash runway through year-end 2026","length":97,"tagName":"p","attribs":{}},{"type":"text","content":"A Type A meeting has been scheduled between Pierre Fabre Pharmaceuticals and the FDA","length":84,"tagName":"p","attribs":{}},{"type":"text","content":"THOUSAND OAKS, Calif., March 16, 2026--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year 2025 and business updates.","length":389,"tagName":"p"},{"type":"text","content":""We continue to focus on streamlining our costs and liabilities, allowing us to be a nimbler, fit for purpose organization," said Cokey Nguyen Ph.D., President and Chief Executive Officer of Atara. "With the adjustments we have made we are able to focus on supporting our partner, Pierre Fabre Pharmaceuticals, as they work towards addressing the concerns in the latest Complete Response Letter with the agency. We strongly believe that tabelecleucel can bring substantial benefit to post-transplant lymphoproliferative disease patients and we are committed to supporting Pierre Fabre Pharmaceuticals as they get this life-saving drug to the finish line in the U.S."","length":686,"tagName":"p"},{"type":"text","content":"Tabelecleucel (tab-cel® or Ebvallo™) for Post-Transplant Lymphoproliferative Disease (PTLD)","length":91,"tagName":"p"},{"...